Melanoma Clinical Trials in San Antonio

Showing 81-100 of 108 trials

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

NCT00110994

This is a randomized, double blind, placebo controlled, multicenter, phase II study to compare the anti-tumor activity as measured by progression-free survival (PFS) and the tolerability of Sorafenib in combination with Dacarbazine (DTIC) versus DTIC in combination with placebo in subjects with unresectable Stage III or Stage IV melanoma who have not received prior cytotoxic chemotherapy. A total of approximately 98 subjects will be randomized to receive DTIC + Sorafenib or DTIC + Placebo.

CancerMelanoma

Bayer101 participantsStarted Apr 2005

Tucson, Arizona, United States • Aurora, Colorado, United States • Lakeland, Florida, United States +11 more locations

COMPLETEDPHASE2< 1 mile

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

NCT00498836

Patients with metastatic malignant melanoma will receive CP-4055 200 mg/m2/day intravenously (IV) on Day 1-5 every four weeks and sorafenib 400 mg b.i.d. (twice daily) every day until complete response or disease worsening/progressing.

Malignant Melanoma

Clavis Pharma18 participantsStarted Mar 2007

Pittsburgh, Pennsylvania, United States • San Antonio, Texas, United States • Oslo, Norway +3 more locations

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Melanoma Trials in Other Cities

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Phase II, 2nd Line Melanoma - RAND Monotherapy

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Vaccine Therapy in Treating Patients With Malignant Melanoma

A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma

A Study of Tasisulam in Treating Participants With Malignant Melanoma

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Other Conditions in San Antonio